A recombinant, long-acting monoclonal antibody that provides passive immunization against respiratory syncytial virus (RSV) by binding to the prefusion RSV fusion (F) protein, thereby preventing viral entry into host cells. It is indicated for the prevention of RSV-associated lower respiratory tract disease in neonates and infants during their first RSV season, and in certain high-risk children entering a subsequent season. Beyfortus is administered as a single intramuscular dose per RSV season (weight-based), offering season-long protection without inducing active immunity, and serves as an alternative to monthly palivizumab injections.
Synonyms
Nirsevimab